Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts

Trends in Molecular Medicine

Volumn 13, Issue 8, 2007, Pages 345-352

  Noël, Agnès ^a   Jost, Maud ^a   Lambert, Vincent ^b   Lecomte, Julie ^a   Rakic, Jean Marie ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; ANGIOGENESIS INHIBITOR; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; BEVASIRANIB; ENDOSTATIN; EVIZON; MACROGOL; PEGAPTANIB; PHOTOSENSITIZING AGENT; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE; RANIBIZUMAB; SORAFENIB; SQUALAMINE; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165; VATALANIB;

ANGIOGENESIS; ARGON LASER; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; LASER COAGULATION; NONHUMAN; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION;

AGING; ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; HUMANS; INFLAMMATION; MACULAR DEGENERATION;

EID: 34547222973     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.06.005     Document Type: Review

References (81)

1. Bressler N.M. Age-related macular degeneration is the leading cause of blindness.... J. Am. Med. Assoc. 291 (2004) 1900-1901
2. Rattner A., et al. Macular degeneration: recent advances and therapeutic opportunities. Nat. Rev. Neurosci. 7 (2006) 860-872
3. Haddad S., et al. The genetics of age-related macular degeneration: A review of progress to date. Surv. Ophthalmol. 51 (2006) 316-363
4. Haines J.L., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005) 419-421
5. Dewan, A. et al. Two genetic pathways for age-related macular degeneration. Curr. Opin. Genet. Dev. (in press)
6. Ferrara N., et al. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
7. Gragoudas E.S., et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (2004) 2805-2816
8. Bashshur Z.F., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am. J. Ophthalmol. 142 (2006) 1-9
9. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N. Engl. J. Med. 355 (2006) 1409-1412
10. Rosenfeld P.J., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1419-1431
11. Bressler N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 119 (2001) 198-207
12. Hooper C.Y., et al. New treatments in age-related macular degeneration. Clin. Experiment. Ophthalmol. 31 (2003) 376-391
13. Verheul H.M., et al. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 7 (2007) 475-485
14. Tobe T., et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 153 (1998) 1641-1646
15. Malek G., et al. Apolipoprotein E allele-dependent pathogenesis: A model for age-related retinal degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11900-11905
16. Imamura Y., et al. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: A model of age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11282-11287
17. Spaide R.F. Rationale for combination therapies for choroidal neovascularization. Am. J. Ophthalmol. 141 (2006) 149-156
18. Lambert V., et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am. J. Pathol. 161 (2002) 1247-1253
19. Zhou J., et al. Neutrophils promote experimental choroidal neovascularization. Mol. Vis. 11 (2005) 414-424
20. Espinosa-Heidmann D.G., et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 44 (2003) 3586-3592
21. Ambati J., et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 9 (2003) 1390-1397
22. Caicedo A., et al. Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. Exp. Eye Res. 81 (2005) 38-47
23. Espinosa-Heidmann D.G., et al. Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4914-4919
24. Sengupta N., et al. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4908-4913
25. Chan-Ling T., et al. Hematopoietic stem cells provide repair functions after laser-induced Bruch's membrane rupture model of choroidal neovascularization. Am. J. Pathol. 168 (2006) 1031-1044
26. Harris J.R., et al. Bone marrow-derived cells home to and regenerate retinal pigment epithelium after injury. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2108-2113
27. Rakic J.M., et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell. Mol. Life Sci. 60 (2003) 463-473
28. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
29. Tong J.P., et al. Contribution of VEGF and PEDF to choroidal angiogenesis: A need for balanced expressions. Clin. Biochem. 39 (2006) 267-276
30. Autiero M., et al. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9 (2003) 936-943
31. Cao Y., et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J. Biol. Chem. 271 (1996) 3154-3162
32. Makinen, T. et al. Molecular mechanisms of lymphatic vascular development. Cell. Mol. Life Sci. (in press)
33. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 105 (2000) 17-19
34. Hattori K., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8 (2002) 841-849
35. Luttun A., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8 (2002) 831-840
36. Kwak N., et al. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3158-3164
37. Reich S.J., et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9 (2003) 210-216
38. Vinores S.A., et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J. Cell. Physiol. 206 (2006) 749-758
39. Luttun A., et al. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?. Biochim. Biophys. Acta 1654 (2004) 79-94
40. Ambati B.K., et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443 (2006) 993-997
41. Oshima Y., et al. Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J. Cell. Physiol. 201 (2004) 393-400
42. Okamoto N., et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am. J. Pathol. 151 (1997) 281-291
43. Otani A., et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc. Res. 64 (2002) 162-169
44. Rakic J.M., et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44 (2003) 3186-3193
45. Carmeliet P., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7 (2001) 575-583
46. Hera R., et al. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am. J. Ophthalmol. 139 (2005) 589-596
47. He S., et al. Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 46 (2005) 4772-4779
48. Bix G., et al. Matrix revolutions: 'tails' of basement-membrane components with angiostatic functions. Trends Cell Biol. 15 (2005) 52-60
49. Uno K., et al. Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. Br. J. Ophthalmol. 90 (2006) 48-54
50. Bhutto I.A., et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 45 (2004) 1544-1552
51. Bhutto I.A., et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp. Eye Res. 82 (2006) 99-110
52. Mori K., et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 43 (2002) 2428-2434
53. Apte R.S., et al. Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest. Ophthalmol. Vis. Sci. 45 (2004) 4491-4497
54. Overall C.M., et al. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 25 (2006) 69-75
55. Folgueras A.R., et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 48 (2004) 411-424
56. Fariss R.N., et al. Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am. J. Pathol. 150 (1997) 323-328
57. Langton K.P., et al. Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells. Hum. Mol. Genet. 14 (2005) 3579-3586
58. Lambert V., et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 15 (2001) 1021-1027
59. Rakic J.M., et al. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44 (2003) 1732-1739
60. Lambert V., et al. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2791-2797
61. Berglin L., et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest. Ophthalmol. Vis. Sci. 44 (2003) 403-408
62. Lambert V., et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 17 (2003) 2290-2292
63. Heissig B., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand. Cell 109 (2002) 625-637
64. Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. (in press)
65. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
66. Jain R.K., et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3 (2006) 24-40
67. Schmidt-Erfurth U., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4473-4480
68. Luttun A., et al. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann. N. Y. Acad. Sci. 979 (2002) 80-93
69. Bradley J., et al. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10 (2007) 141-148
70. Husain D., et al. Safety and efficacy of intravitreal injection of rhuFab VEGF V2 in combination with verteporfin PDT experimental choroidal neovascularization. Arch. Ophthalmol. 123 (2005) 509-516
71. Augustin A.J., et al. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 243 (2005) 9-12
72. Ciulla T.A., et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol. 119 (2001) 399-404
73. Sengupta N., et al. Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors. Invest. Ophthalmol. Vis. Sci. 46 (2005) 343-348
74. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol. 109 (1991) 1232-1241
75. Bressler N.M., et al. Age related macular degeneration - New hope for a common problems comes from photodynamic therapy. BMJ 321 (2000) 1425-1427
76. Michels S., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (2005) 1035-1047
77. Nguyen Q.D., et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 1522-1532
78. Shen J., et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 13 (2006) 225-234
79. Campochiaro P.A., et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial. Hum. Gene Ther. 17 (2006) 167-176
80. Connolly B., et al. Squalamine lactate for exudative age-related macular degeneration. Ophthalmol. Clin. North Am. 19 (2006) 381-391
81. Slakter J.S., et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 113 (2006) 3-13